中文
English
한국어
日本語
Español
Français
Русский
| カタログ番号 | MB996107 |
|---|---|
| 種反応性 | Mouse |
| アプリケーション | Blocking, FCM, IP |
| 宿主種 | Rat |
| クローン性 | Monoclonal |
| アイソタイプ | IgG2a, kappa |
| クローンID | 1D3 |
| ターゲット | B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12 |
| エンドトキシンレベル | < 10 EU/mg |
| 純度 | >95% as determined by SDS-PAGE. |
| 精製 | Protein A/G purified from cell culture supernatant. |
| アクセッション番号 | P25918 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 背景 | B-lymphocyte antigen CD19 is a ~60 kDa protein. Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. CD19 is the therapeutic target of tafasitamab (Monjuvi). 1. Wang, Y. et al. (2002) Immunity 17, 501-14. PMID: 12387743 2. Ishiura, N. et al. (2010) European journal of immunology 40, 1192-204. PMID: 20101619 3. Buhl, AM. et al. (1997) The Journal of experimental medicine 186, 1897-910. PMID: 9382888 4. Engel, P. et al. (1995) Immunity 3, 39-50. PMID: 7542548 5. Rickert, RC. et al. (1995) Nature 376, 352-5. PMID: 7543183 6. Sato, S. et al. (1997) Journal of immunology (Baltimore, Md. : 1950) 159, 3278-87. PMID: 9317126 |
| 注意事項 | For research use only. |
SDS-PAGE for Anti-Mouse CD19 Antibody (1D3)
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206
